Skip to main content

Table 1 Patient characteristics

From: Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis

Characteristic

Afatinib-naïve

Patients, number

51

Gender, number (%)

 Male

48 (94%)

 Female

3 (6%)

 Age, median (range) (years)

59.2 (34.4–74.0)

Cancer type, number (%)

 Oral cavity

36 (70%)

 Oropharynx

8 (16%)

 p16 status: ( +) / (-) / NA

1 / 5 / 2

 Hypopharynx

7 (14%)

Habits, number (%)

 Alcohol drinking

35 (69%)

 Betel nut chewing

36 (71%)

 Cigarette smoking

44 (86%)

Definitive treatment

 Surgery–CCRT

35 (69%)

 Definitive CCRT

11 (21%)

 Surgery alone

5 (10%)

Time from definitive therapy to recurrence/metastases (%)

 0–90 days

10 (20%)

 91–180 days

16 (31%)

  ≥ 181 days

25 (49%)

Cetuximab, number (%)

 Naïve

44 (86%)

 Induction

1 (2%)

 Bio-RT

1 (2%)

 For recurrent/metastatic disease

5 (10%)

Pembrolizumab, dose/cycle

 200 mg fixed dose

27 (52%)

 2 mg/kg

25 (48%)

Pembrolizumab, cycles

 1–3 cycles

13 (25%)

 4 cycles

34 (67%)

 5–7 cycles

4 (8%)